top of page
Leading the Way in Intratumoral Radiotherapeutics
News
Categories
Sign up
Featured Posts
Archive
Follow Us
Alpha Tau Medical Announces First Quarter 2022 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $104 million in gross proceeds-...
May 26, 2022
Alpha Tau Medical Announces Full Year 2021 Financial Results and Provides Corporate Update
-Debuted as publicly-traded oncology company in March 2022 under symbol DRTS while raising approximately $90 million in gross proceeds-...
Mar 28, 2022
Alpha Tau Medical Ltd. Appoints Ruth Alon to its Board of Directors
JERUSALEM, March 21, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha...
Mar 22, 2022
Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination
Alpha Tau Is Expected to Commence Trading on Nasdaq Under the Ticker "DRTS" on March 8, 2022 JERUSALEM and WILMINGTON, Del., March 7,...
Mar 8, 2022
New Alpha DaRT Research Collaboration on Immune Stimulation in the Treatment of Breast Cancer
JERUSALEM, Jan 20, 2022 – Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha...
Jan 20, 2022
Results of First US Clinical Trial of Alpha DaRT™
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT™ in Malignant Skin & Soft Tissue Cancers, Showing Complete Response...
Jan 10, 2022
Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
JERUSALEM, Dec. 31, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Jan 3, 2022
Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
JERUSALEM, Nov. 3, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Nov 4, 2021
Completion of Enrollment in 1st US Clinical Trial & Achievement of 1st Primary Objective
JERUSALEM, Oct. 25, 2021 -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha...
Oct 26, 2021
Alpha Tau Receives FDA's Breakthrough Device Designation for the Treatment of Recurrent GBM
JERUSALEM, Oct. 8, 2021 -- Alpha Tau Medical, the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, is pleased to...
Oct 12, 2021
bottom of page